9/22/25 - $crm - worth a closer look?

480
9/22/25 :: VROCKSTAR :: CRM
worth a closer look?

- seems like the market wants the mega caps and the micro memes, but nothing in between
- that's what brought me back to $NYSE:FI in the last few days (it's about a 20% position or 8% leveraged 2.5-1 on a series of jan '28 ITM leaps)
- now i'm looking at CRM and saying, let's have a look
- anything that's doing >6% fcf (this is even closer to 6.5%) and growing MSD nevermind HSD like this one should get another look
- i get the sense fund mgrs r being "forced" to index toward higher mcap factor and ignore these, despite what actives would prefer
- and you get a really nice setup potentially into YE where one of two things happens (let's use $fi/CRM as similar types - $100 bn one $230 bn other).
a. mkt continues to bleed/ eschew these to chase mag7 performance and in which case you get an easy '26 play esp at end of year into 1H26 as rotation out of megas will inevitably mean they perform weaker and you get a reverse of this momentum
b. these caps actually get a bid - which is my suspicion - as you get highly liquid mega caps that might drip 5-10% at most (we'll get a few bumps along the road - and the longer we go without these... the higher these "alts" that r 100-300bn will run) and if we do take a sneeze, we'll get a nice dip buy entry again, for YE play.
- i do think all roads lead higher here
- and while "AI" might be an issue, sure - for names like $NYSE:FI and CRM, these co's have serious initiatives that r already showing fruit and i think dominant platforms w HSD momentum in a weak macro (ex-B2B pure-AI) is pretty high quality and gives u booster re-ratings when we do eventually get more substantial cuts. remember - these cuts won't help NVDA as much as they help customers for $fi... $crm... types. and that's where you go from 8-9% growth for both of these toward 15+% and they'll re-rate toward 4-5% fcf yield and stock will be 50% higher.

V

Declinazione di responsabilità

Le informazioni e le pubblicazioni non sono intese come, e non costituiscono, consulenza o raccomandazioni finanziarie, di investimento, di trading o di altro tipo fornite o approvate da TradingView. Per ulteriori informazioni, consultare i Termini di utilizzo.